Payments and accruals for achievement of various clinical development, regulatory and commercial milestones
Mirum Pharmaceuticals, Inc.·Products & Services·1 segment
Breakdown
Segments
VolixibatView metric
| Segment | Q1 '25 | Q1 '26 |
|---|---|---|
| Volixibat | $91.5M | $101.5M |
| Total | $91.5M | $101.5M |